Dexcom®

CGM First™
A New Standard of Diabetes Care

The COMISAIR Study[1]

CGM for MDI patients? Yes, they can benefit, *too.*

Results from this year-long study showed that continuous glucose monitoring (CGM)–not the insulin delivery method–drives A1C reduction.

Study Objectives and Methods

Objective:
Compare efficacy of MDI* and pump insulin regimens augmented by CGM vs. SMBG†.

* Multiple daily injections
† Self-monitoring of blood glucose

Research Design/Methods:
- 1-Year prospective clinical trial
- 65 participants with type 1 diabetes
- Adults (>18 years) with A1Cs ranging from 7%-10%
- Participants divided into four groups (see chart below)



Group	Baseline A1C	52 Weeks	Mean Difference
MDI + SMBG (n=18)	8.3	8.0	-0.3
Pump + SMBG (n=20)	8.4	7.9	-0.5
MDI + CGM (n=12)	8.5	**7.2**	-1.3
Pump + CGM (n=15)	8.2	**7.1**	-1.1

RESULTS

GREATER A1C REDUCTION
Patients on **MDI + CGM** saw greater improvement than those on Pump Therapy + SMBG

REDUCED HYPOGLYCEMIA
25% reduction of time spent in hypoglycemia in **CGM-augmented group** compared to baseline

INCREASED TIME SPENT IN TARGET RANGE
38% increase in time spent in range (72 mg/dL-180 mg/dL) in **CGM-augmented group** compared to baseline

CGM First™

Recognized as the standard of care in diabetes management by ADA, AACE and the Endocrine Society, CGM use has been proven to **reduce A1C without increasing risk of hypoglycemia regardless of insulin delivery method.**[2-4] When initiating or adjusting insulin regimens for your patients, CGM provides real-time insights for better glycemic outcomes. Optimize your patients' treatment plans and prescribe a Dexcom CGM System today.

For more information, visit dexcom.com/cgmfirst

References
1 Šoupal J, Petruželková L, Flekač M et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technology & Therapeutics. 2016;18(9):532-538. 2 American Diabetes Association. (2016). Glycemic Targets. Standards of Medical Care. Diabetes Care, S39-S40. 3 Fonseca V, Grunberger G, Anhalt H et al. CONTINUOUS GLUCOSE MONITORING: A CONSENSUS CONFERENCE OF THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY. Endocr Pract. 2016;22(8):1008-1021.4 Peters A, Ahmann A, Battelino T et al. Diabetes Technology—Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2016:jc.2016-2534.

BRIEF SAFETY STATEMENT: The Dexcom G5 Mobile Continuous Glucose Monitoring System (the "System") is a glucose monitoring system indicated for detecting trends and tracking patterns in persons (age 2 years and older) with diabetes. CONTRAINDICATIONS: Remove the System (sensor, transmitter, and receiver) before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, or high-frequency electrical heat (diathermy) treatment. The System is MR Unsafe. Do not bring any portion of the System into the MR environment. Taking acetaminophen while wearing the sensor may falsely raise your sensor glucose readings. WARNING: Do not use the System for treatment decisions. The System does not replace a blood glucose meter. The System is not approved for use in pregnant women, persons on dialysis or critically ill persons. If a sensor breaks and no portion of it is visible above the skin, do not attempt to remove it. Seek professional medical help if you have infection or inflammation. Report broken sensors to Dexcom Technical Support. Sensor placement is not approved for sites other than under the skin of the belly (ages 2 years and older) or upper buttocks (ages 2-17 years). Your smart device's internal settings override your Dexcom app settings. Accessory devices (like a smart watch) might override your smart device's alert and notification settings. The Share feature must be turned "On" with an active internet connection to communicate glucose information to a Follower. The Follower must download and install the Dexcom Follow App onto a separate smart device with an active internet connection to receive data. Contact Dexcom Toll Free at 877-339-2664 or www.dexcom.com for detailed indications for use and safety information.

LBL014449 Rev001